Percutaneous coronary intervention versus medical therapy in stable angina: a matched cohort study
Conclusions
PCI plus OMT was associated with higher rate of primary endpoint of MI, stroke, cardiac death as compared with OMT alone in patients with pure stable angina at 9.3-year follow-up in large population. (Source: Heart)
Source: Heart - April 25, 2024 Category: Cardiology Authors: Jo, S.-H., Kim, H., Kim, H.-J., Lee, M.-H., Seo, W.-W., Kim, M., Kim, H.-L. Tags: Coronary artery disease Source Type: research
Real-World Experience and Outcomes with Percutaneous Coronary Intervention for Protected versus Unprotected Left Main Coronary Artery Disease: Insights from the VA CART Program
Practice patterns and outcomes of protected left main (PLM) and unprotected left main (ULM) percutaneous coronary intervention (PCI) are not well defined in contemporary US clinical practice. Data collected from all Veteran Affairs (VA) catheterization laboratories participating in the Clinical Assessment Reporting and Tracking Program between 2009 and 2019. The analysis included 4,351 patients undergoing left main PCI, of which 1,306 pairs of PLM and ULM PCI were included in a propensity matched cohort. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 25, 2024 Category: Cardiology Authors: Pedro Engel Gonzalez, Annika Hebbe, Yasin Hussain, Rohan Khera, Subhash Banerjee, Mary E Plomondon, Stephen W. Waldo, Steven E. Pfau, Jeptha P. Curtis, Samit M. Shah Source Type: research
Impact of periprocedural myocardial injury on long-term outcomes after percutaneous coronary intervention requiring atherectomy
Percutaneous coronary intervention (PCI) is the most frequent type of coronary revascularization, and is performed with the aim of relieving anginal symptoms, reducing the need for urgent revascularization, and lowering the risk of spontaneous myocardial infarction (1,2). Conversely, patients undergoing PCI are at risk of procedure-related myocardial injury, which may offset these benefits or even worsen the clinical course. Myocardial injury following PCI is assessed by the rise in cardiac biomarkers, commonly cardiac troponin. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 25, 2024 Category: Cardiology Authors: Hiroki Emori, Yasutsugu Shiono, Nehiro Kuriyama, Yasuhiro Honda, Kosuke Kadooka, Takeaki Kudo, Kenji Ogata, Toshiyuki Kimura, Kensaku Nishihira, Atsushi Tanaka, Yoshisato Shibata Source Type: research
Percutaneous intravascular micro-axial blood pump: current state and perspective from engineering view
AbstractThe utilization of a minimally invasively placed catheter-mounted intravascular micro-axial flow blood pump (IMFBP) is increasing in the population with advanced heart failure. The current development of IMFBPs dates back around the 1990s, namely the Hemopump with a wire-drive system and the Valvopump with a direct-drive system. The wire-drive IMFBPs can use a brushless motor in an external console unit to transmit rotational force through the drive wire rotating the impeller inside the body. The direct-drive IMFBPs require an ultra-miniature and high-power brushless motor. Additionally, the direct-drive system nec...
Source: Journal of Artificial Organs - April 25, 2024 Category: Transplant Surgery Source Type: research
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention
Platelets. 2024 Dec;35(1):2327835. doi: 10.1080/09537104.2024.2327835. Epub 2024 Apr 24.ABSTRACTPercutaneous coronary intervention (PCI) patients combined with thrombocytopenia (TP) are usually considered to be at low ischemic risk, receiving less proper antiplatelet therapy. However, recent studies reported a paradoxical phenomenon that PCI patients with TP were prone to experience thrombotic events, while the mechanisms and future treatment remain unclear. We aim to investigate whether inflammation modifies platelet reactivity among these patients. Consecutive 10 724 patients undergoing PCI in Fuwai Hospital were enrolle...
Source: Platelets - April 24, 2024 Category: Hematology Authors: Kailun Yan Jiawen Li Yulong Li Pei Zhu Xiaofang Tang Deshan Yuan Yuejin Yang Runlin Gao Jinqing Yuan Xueyan Zhao Source Type: research
Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography
CONCLUSION: The findings indicated that elevated lipoprotein(a) had no obvious relationship with hypertension and obesity. Elevated lipoprotein(a) increases the risk of high total cholesterol, high LDL‑c, and premature CAD, and increases the occurrence and severity of coronary heart disease.PMID:38658408 | DOI:10.1007/s00059-024-05247-0 (Source: Herz)
Source: Herz - April 24, 2024 Category: Cardiology Authors: Azhi ShaMa Chunmei Xu Yingying Huang Chunlan Ma Jingyue Hu Zhuxin Li Chunyu Zeng Source Type: research
The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
CONCLUSIONS: The CHADS-P2A2RC risk score is valuable in discriminating high-ischemic-risk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.PMID:38654565 | DOI:10.4070/kcj.2023.0268 (Source: Korean Circulation Journal)
Source: Korean Circulation Journal - April 24, 2024 Category: Cardiology Authors: Pil Sang Song Seok-Woo Seong Ji-Yeon Kim Soo Yeon An Mi Joo Kim Kye Taek Ahn Seon-Ah Jin Jin-Ok Jeong Jeong Hoon Yang Joo-Yong Hahn Hyeon-Cheol Gwon Woo Jin Jang Hyuck Jun Yoon Jang-Whan Bae Woong Gil Choi Young Bin Song Source Type: research
Long-term outcomes following double kissing crush or mini-culotte stenting for complex coronary bifurcation lesions: the EVOLUTE-CRUSH IV study
CONCLUSION: At long-term follow-up, the rates of TLF and MACCE were 17.4% and 20%, respectively. However, long-term TLF was significantly higher in patients treated with MCT than those treated with the DKC technique, primarily due to a more frequent occurrence of clinically driven TLR.PMID:38656396 | DOI:10.1007/s00059-024-05244-3 (Source: Herz)
Source: Herz - April 24, 2024 Category: Cardiology Authors: Mustafa Y ıldız Ahmet G üner G ökhan Demirci Ahmet Ya şar Çizgeci Serkan Kahraman Hasan Ali Barman Fatih Uzun Cemalettin Akman Emre Ayd ın Abdullah Do ğan İrem Türkmen Muhammed Mustafa Y ıldız Mehmet Ert ürk Source Type: research
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention
Platelets. 2024 Dec;35(1):2327835. doi: 10.1080/09537104.2024.2327835. Epub 2024 Apr 24.ABSTRACTPercutaneous coronary intervention (PCI) patients combined with thrombocytopenia (TP) are usually considered to be at low ischemic risk, receiving less proper antiplatelet therapy. However, recent studies reported a paradoxical phenomenon that PCI patients with TP were prone to experience thrombotic events, while the mechanisms and future treatment remain unclear. We aim to investigate whether inflammation modifies platelet reactivity among these patients. Consecutive 10 724 patients undergoing PCI in Fuwai Hospital were enrolle...
Source: Platelets - April 24, 2024 Category: Hematology Authors: Kailun Yan Jiawen Li Yulong Li Pei Zhu Xiaofang Tang Deshan Yuan Yuejin Yang Runlin Gao Jinqing Yuan Xueyan Zhao Source Type: research
The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
CONCLUSIONS: The CHADS-P2A2RC risk score is valuable in discriminating high-ischemic-risk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.PMID:38654565 | DOI:10.4070/kcj.2023.0268 (Source: Korean Circulation Journal)
Source: Korean Circulation Journal - April 24, 2024 Category: Cardiology Authors: Pil Sang Song Seok-Woo Seong Ji-Yeon Kim Soo Yeon An Mi Joo Kim Kye Taek Ahn Seon-Ah Jin Jin-Ok Jeong Jeong Hoon Yang Joo-Yong Hahn Hyeon-Cheol Gwon Woo Jin Jang Hyuck Jun Yoon Jang-Whan Bae Woong Gil Choi Young Bin Song Source Type: research
Long-term outcomes following double kissing crush or mini-culotte stenting for complex coronary bifurcation lesions: the EVOLUTE-CRUSH IV study
CONCLUSION: At long-term follow-up, the rates of TLF and MACCE were 17.4% and 20%, respectively. However, long-term TLF was significantly higher in patients treated with MCT than those treated with the DKC technique, primarily due to a more frequent occurrence of clinically driven TLR.PMID:38656396 | DOI:10.1007/s00059-024-05244-3 (Source: Herz)
Source: Herz - April 24, 2024 Category: Cardiology Authors: Mustafa Y ıldız Ahmet G üner G ökhan Demirci Ahmet Ya şar Çizgeci Serkan Kahraman Hasan Ali Barman Fatih Uzun Cemalettin Akman Emre Ayd ın Abdullah Do ğan İrem Türkmen Muhammed Mustafa Y ıldız Mehmet Ert ürk Source Type: research
Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography
CONCLUSION: The findings indicated that elevated lipoprotein(a) had no obvious relationship with hypertension and obesity. Elevated lipoprotein(a) increases the risk of high total cholesterol, high LDL‑c, and premature CAD, and increases the occurrence and severity of coronary heart disease.PMID:38658408 | DOI:10.1007/s00059-024-05247-0 (Source: Herz)
Source: Herz - April 24, 2024 Category: Cardiology Authors: Azhi ShaMa Chunmei Xu Yingying Huang Chunlan Ma Jingyue Hu Zhuxin Li Chunyu Zeng Source Type: research
Antiplatelet therapy for treatment of coronary artery disease in older patients
Arch Cardiovasc Dis. 2024 Apr 12:S1875-2136(24)00055-X. doi: 10.1016/j.acvd.2024.02.008. Online ahead of print.ABSTRACTCoronary artery disease in older patients is more frequently diffuse and complex, and is often treated by percutaneous coronary intervention on top of medical therapy. There are currently no specific recommendations for antiplatelet therapy in patients aged≥75 years. Aspirin remains pivotal, and is still indicated as a long-term treatment after percutaneous coronary intervention. In addition, a P2Y12 inhibitor is administered for 6-12 months according to clinical presentation. Age is a minor bleeding ris...
Source: Archives of Cardiovascular Diseases - April 24, 2024 Category: Cardiology Authors: Quentin Fischer Vincent Pham Gabriel Seret Pierre Brami Fabien Picard Olivier Varenne Source Type: research
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention
Platelets. 2024 Dec;35(1):2327835. doi: 10.1080/09537104.2024.2327835. Epub 2024 Apr 24.ABSTRACTPercutaneous coronary intervention (PCI) patients combined with thrombocytopenia (TP) are usually considered to be at low ischemic risk, receiving less proper antiplatelet therapy. However, recent studies reported a paradoxical phenomenon that PCI patients with TP were prone to experience thrombotic events, while the mechanisms and future treatment remain unclear. We aim to investigate whether inflammation modifies platelet reactivity among these patients. Consecutive 10 724 patients undergoing PCI in Fuwai Hospital were enrolle...
Source: Platelets - April 24, 2024 Category: Hematology Authors: Kailun Yan Jiawen Li Yulong Li Pei Zhu Xiaofang Tang Deshan Yuan Yuejin Yang Runlin Gao Jinqing Yuan Xueyan Zhao Source Type: research
Antiplatelet therapy for treatment of coronary artery disease in older patients
Arch Cardiovasc Dis. 2024 Apr 12:S1875-2136(24)00055-X. doi: 10.1016/j.acvd.2024.02.008. Online ahead of print.ABSTRACTCoronary artery disease in older patients is more frequently diffuse and complex, and is often treated by percutaneous coronary intervention on top of medical therapy. There are currently no specific recommendations for antiplatelet therapy in patients aged≥75 years. Aspirin remains pivotal, and is still indicated as a long-term treatment after percutaneous coronary intervention. In addition, a P2Y12 inhibitor is administered for 6-12 months according to clinical presentation. Age is a minor bleeding ris...
Source: Archives of Cardiovascular Diseases - April 24, 2024 Category: Cardiology Authors: Quentin Fischer Vincent Pham Gabriel Seret Pierre Brami Fabien Picard Olivier Varenne Source Type: research
